Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Cellectar Biosciences reported a case study of a heavily pretreated double-hit DLBCL patient who achieved a complete response lasting more than eight years after a single 57.5 mCi dose of iopofosine I 131. The 53-year-old patient, after four prior therapy lines and a stem cell transplant, showed no disease progression and required no additional anticancer therapy as of May 2026, with expected hematologic toxicities that all resolved.
Key figures
- Drug Name
- iopofosine I 131
- Phase Of Trial
- Phase 3
- Single dose
- 57.5 mCi (March 20, 2018)
- Duration of response
- more than eight years
- Fda submission target
- first half of 2027
- Phase3 wm dosing start
- Q1 2027
- Prior lines of therapy
- 4
- Target lesion baseline
- 825 mm³ to 0 mm³ by Day 85
- Time to complete response
- Day 85
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.